Formulari Ubat KKM (FUKKM)

# Generic Name MDC Category Indications Dosage
31 Alendronate Sodium 70 mg and Cholecalciferol 5600 IU Tablet M05BB03972T1002XX A* Osteoporosis in postmenopausal women with a history of vertebral fracture and whom oestrogen replacement therapy is contraindicated. Review treatment after 2 years and if there is positive response, treatment may be continued up to 5 years and then re-evaluate. Treatment should be stopped if there is no positive response after 5 years. Otherwise, patient needs to be given drug holiday for 1 to 2 years and then continue treatment shall the benefit outweigh the risk. 1 tablet once weekly [70mg/5600 IU]. Patient should receive supplemental calcium or vitamin D, if dietary vitamin D inadequate. The tablet should be taken at least half and hour before the first food, beverage, or medication of the day with plain water only. To facilitate delivery to stomach and thus reduce the potential for esophageal irritation, it should only be swallowed upon arising for the day with a full glass of water and patient should not lie down for at least 30 minutes and until after their first food of the day.
32 Alendronate Sodium 70 mg Tablet M05BA04520T1001XX A* Osteoporosis in postmenopausal women with a history of vertebral fracture and whom oestrogen replacement therapy is contraindicated. Review treatment after 2 years and if there is positive response, treatment may be continued up to 5 years and then re-evaluate. Treatment should be stopped if there is no positive response after 5 years. Otherwise, patient needs to be given drug holiday for 1 to 2 years and then continue treatment shall the benefit outweigh the risk. 70 mg once weekly. Swallow the tablet whole with a full glass of plain water only on an empty stomach at least 30 minutes before breakfast (and any other oral medication); stand or sit upright for at least 30 minutes and do not lie down until after eating breakfast
33 Alfacalcidol 0.25 mcg Capsule A11CC03000C1001XX A/KK i) Renal osteodystrophy in patients on haemodialysis ii) Hypoparathyroidism and pseudohypoparathyroidism iii) Adjunct to the management of tertiary hyperparathyroidism iv) Rickets and osteomalacia v) Osteoporosis Initial dose ADULT and CHILD above 20kg body weight : 1 mcg daily; CHILD under 20kg body weight : 0.05 mcg/kg/day. Maintenance dose : 0.25 mcg to 2 mcg daily
34 Alfacalcidol 1 mcg Capsule A11CC03000C1002XX A/KK i) Renal osteodystrophy in patients on haemodialysis ii) Hypoparathyroidism and pseudohypoparathyroidism iii) Adjunct to the management of tertiary hyperparathyroidism iv) Rickets and osteomalacia v) Osteoporosis Initial dose ADULT and CHILD above 20kg body weight : 1 mcg daily; CHILD under 20kg body weight : 0.05 mcg/kg/day. Maintenance dose : 0.25 mcg to 2 mcg daily
35 Alfacalcidol 2 mcg/ml Drops A11CC03000D5001XX A* i) Renal osteodystrophy in patients on haemodialysis ii) Hypoparathyroidism and pseudohypoparathyroidism iii) Adjunct to the management of tertiary hyperparathyroidism iv) Rickets and osteomalacia v) Osteoporosis NEONATES : 0.1 mcg/kg/day
36 Alfacalcidol 2 mcg/ml Injection A11CC03000P3001XX A* Treatment of: i) Renal osteodystrophy in patients on haemodialysis ii) Hypoparathyroidism and pseudohypoparathyroidism iii) Adjunct to the management of tertiary hyperparathyroidism iv) Rickets and osteomalacia v) Osteoporosis Adult: Initially, 1 mcg daily. Maintenance: 0.25-1 mcg daily. Child: Premature infants and neonates: 0.05-0.1 mcg/kg daily; <20 kg: 0.05 mcg/kg daily. Elderly: 0.5 mcg daily.
37 Alfentanil HCl 0.5 mg/ml Injection N01AH02110P3001XX A* For use as short acting narcotic analgesic in short procedures and day-care surgical procedures Initial dose: 20 - 40 mcg/kg. Supplemental dose: 15 mcg/kg or infusion 0.5 - 1.0 mcg/kg/min
38 Alfuzosin HCl 10 mg Tablet G04CA01110T1001XX A* Treatment of functional symptoms related with benign prostatic hypertrophy (BPH) 05/6/20/RR/ Update contract validity 10 mg once a day pre bed
39 Alglucosidase alfa 5 mg/ml Injection A16AB07000P4001XX A* Infantile-onset Pompe disease 20 mg/kg of body weight administered once every 2 weeks as an intravenous infusion. Monitoring It is suggested that patients be monitored periodically for IgG antibody formation. Patients who experience Infusion-associated reactions suggestive of hypersensitivity may be tested for IgE antibodies to alglucosidase alfa. Treated patients who experience a decrease in benefit despite continued treatment with Alglucosidase Alfa, in whom antibodies are suspected to play a role, may be tested for neutralization of enzyme uptake or activity.
40 Alkaline Nasal Douche R01A000999L5001XX B To remove nasal plug To be diluted with an equal volume of warm water before use
41 All-Trans Retinoic Acid 10 mg Capsule L01XX14000C1001XX A* Acute promyelocytic leukaemia Induction: 45 mg/m2 daily for 30 - 90 days. Maintenance: 45 mg/m2 daily for 2 weeks every 3 months. Renal/or hepatic insufficiency: 25mg/m2 daily for 30-90 days. Refer to protocols
42 Allopurinol 100 mg Tablet M04AA01000T1002XX A/KK i) Frequent and disabling attacks of gouty arthritis (3 or more attacks/year). ii) Clinical or radiographic signs of erosive gouty arthritis. iii) The presence of tophaceous deposits. iii) Urate nephropathy. iv) Urate nephrolithiasis. v) Impending cytotoxic chemotherapy or radiotherapy for lymphoma or leukaemia Initial dose: 50-100 mg daily. Maintenance: 300-900mg daily (depending on renal function).
43 Allopurinol 300 mg Tablet M04AA01000T1001XX A/KK i) Frequent and disabling attacks of gouty arthritis (3 or more attacks/year). ii) Clinical or radiographic signs of erosive gouty arthritis. iii) The presence of tophaceous deposits. iii) Urate nephropathy. iv) Urate nephrolithiasis. v) Impending cytotoxic chemotherapy or radiotherapy for lymphoma or leukaemia Initial dose: 50-100 mg daily. Maintenance: 300-900mg daily (depending on renal function).
44 Alprazolam 0.25 mg Tablet N05BA12000T1001XX A/KK Anxiety disorders 0.25 - 0.5 mg 3 times daily (elderly or delibitated 0.25 mg 2-3 times daily), increased if necessary to a total dose of 3 mg/day. Not recommended for children
45 Alprazolam 0.5 mg Tablet N05BA12000T1002XX A Anxiety disorders 0.25 - 0.5 mg 3 times daily (elderly or delibitated 0.25 mg 2-3 times daily), increased if necessary to a total dose of 3 mg/day. Not recommended for children
46 Alprazolam 1 mg Tablet N05BA12000T1003XX A Anxiety disorders 0.25 - 0.5 mg 3 times daily (elderly or delibitated 0.25 mg 2-3 times daily), increased if necessary to a total dose of 3 mg/day. Not recommended for children
47 Alprostadil 500 mcg/ml Injection C01EA01000P3001XX A* For treatment of congenital heart diseases which are ductus arteriosus dependent 0.05 - 0.1 mcg/kg/min by continuous IV infusion, then decreased to lowest effective dose
48 Alteplase 50 mg per vial Injection B01AD02000P4001XX A* Thrombolytic treatment of acute ischaemic stroke. 0.9 mg/kg (maximum of 90 mg) infused over 60 minutes with 10% of the total dose administered as an initial intravenous bolus. Treatment must be started as early as possible within 4.5 hours after onset of stroke symptoms and after exclusion of intracranial haemorrhage by appropriate imaging technique.
49 Amantadine HCl 100 mg Capsule N04BB01110C1001XX B Parkinson's disease Initial dose: 100 mg daily and is increased to 100 mg twice daily (not later than 4 p.m.) after a week. Elderly over 65 years: less than 100 mg or 100 mg at intervals of more than 1 day
50 Amikacin 125 mg/ml Injection J01GB06183P3003XX A Infections due to susceptible organisms ADULT: (IM or IV): 15 mg/kg/day 8 - 12 hourly for 7 - 10 days. Maximum: 1.5 g/day. CHILD: 15 mg/kg/day 8 - 12 hourly. Maximum: 1.5 g/day. Neonates: Initial loading dose of 10 mg/kg followed by 7.5 mg/kg/day 12 hourly. Maximum 15mg/kg/day
51 Amikacin 250mg/ml Injection J01GB06183P3002XX A Infections due to susceptible organisms ADULT: (IM or IV): 15 mg/kg/day 8 - 12 hourly for 7 - 10 days. Maximum: 1.5 g/day. CHILD: 15 mg/kg/day 8 - 12 hourly. Maximum: 1.5 g/day. Neonates: Initial loading dose of 10 mg/kg followed by 7.5 mg/kg/day 12 hourly. Maximum 15mg/kg/day
52 Amiloride HCl 5 mg & Hydrochlorothiazide 50 mg Tablet C03EA01900T1001XX B i) Diuretic as an adjunct to the management of oedematous states ii) Hypertension i) Initially 1 - 2 tab daily adjusted according to response. Max : 4 tabs daily. ii) 1 -2 tabs daily as a single or divided dose
53 Amino Acids Injection B05BA01910P3001XX A Source of amino acids in patients needing IV nutrition Dose to be individualised. ADULT usually 500-2000 ml by IV. ADULT usual requirement for amino acid: 1-2 g/kg/day
54 Amino Acids with Electrolytes Injection B05BA10910P3002XX A Source of amino acids and electrolytes in patients needing IV nutrition Dose to be individualised. ADULT usual requirement for amino acid 1-2 g/kg/day
55 Amino Acids with Glucose with Electrolytes Injection B05BA10910P3003XX A Source of amino acids, carbohydrate and electrolytes in patients needing IV nutrition Dose to be individualised. ADULT usual requirement for amino acid 1-2 g/kg/day, carbohydrate 4-6 g/kg/day
56 Amino Acids, Glucose and Lipid with Electrolytes Injection B05BA10910P3001XX A Source of amino acids, carbohydrate, lipid and electrolytes in patients needing IV nutrition Dose to be individualised. ADULT: 500 - 2000 ml daily given by IV. ADULT usual requirement for amino acid 1-2 g/kg/ day, carbohydrate 4-6 g/kg/day, lipid 2-3 g/kg/day
57 Aminophylline 25 mg/ml Injection R03DA05000P3001XX B Reversible airways obstruction, acute severe brochospasm Adult: Loading dose: 5 mg/kg (ideal body weight) or 250-500 mg (25 mg/ml) by slow inj or infusion over 20-30 min. Maintenance infusion dose: 0.5 mg/kg/hr. Max rate: 25 mg/min. Child: Loading dose: same as adult dose. Maintenance dose: 6 mth-9 yr: 1 mg/kg/hr and 10-16 yr: 0.8 mg/kg/hr.
58 Amiodarone 200 mg Tablet C01BD01110T1001XX A* Arrhythmias 200 mg 3 times daily for 1 week, then reduced to 200 mg twice daily for another week. Maintenance dose, usually 200 mg daily or the minimum required to control the arrhythmia
59 Amiodarone 50 mg/ml Injection C01BD01110P3001XX A* Arrhythmias when other drugs are contraindicated or ineffective Initial infusion of 5mg/kg via large venous access over 20-120 minutes with ECG monitoring; subsequent infusion given if necessary according to response up to a maximum of 1.2 g in 24 hours
60 Amisulpride 100 mg Tablet N05AL05000T1001XX A* Treatment of psychoses, particularly acute or chronic schizophrenia disorders characterized by positive symptoms(e.g. delusion, hallucinations, thought disorders) and/or negative symptoms(e.g. blunted emotions, emotional and social withdrawal) including when the negative symptoms predominate Predominantly negative episodes: 50-300 mg once daily adjusted according to the patient?s response. Mixed episodes with positive and negative symptoms: 400-800 mg/day in 2 divided doses adjusted according to the patient?s response. Should be taken on an empty stomach (Preferably taken before meals)

Halaman-halaman